Nitrogen Mustards Interim AEGL Document

Total Page:16

File Type:pdf, Size:1020Kb

Nitrogen Mustards Interim AEGL Document NAC\Interim1:11/2007 ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) FOR NITROGEN MUSTARDS (HN1 CAS Reg. No. 538-07-8) (HN2 CAS Reg. No. 51-75-2) (HN3 CAS Reg. No. 555-77-1) INTERIM NITROGEN MUSTARDS (HN-1, HN-2, HN-3) NAC/Interim1:11/2007 PREFACE 1 2 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 3 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous 4 Substances (NAC/AEGL Committee) has been established to identify, review and interpret 5 relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic 6 chemicals. 7 8 AEGLs represent threshold exposure limits for the general public and are applicable to 9 emergency exposure periods ranging from 10 minutes to 8 hours. Three levels — AEGL-1, 10 AEGL-2 and AEGL-3 — are developed for each of five exposure periods (10 and 30 minutes, 1 11 hour, 4 hours, and 8 hours) and are distinguished by varying degrees of severity of toxic effects. 12 The three AEGLs are defined as follows: 13 14 AEGL-1 is the airborne concentration (expressed as parts per million or milligrams per 15 cubic meter [ppm or mg/m3]) of a substance above which it is predicted that the general 16 population, including susceptible individuals, could experience notable discomfort, irritation, or 17 certain asymptomatic, non-sensory effects. However, the effects are not disabling and are 18 transient and reversible upon cessation of exposure. 19 20 AEGL-2 is the airborne concentration (expressed as ppm or mg/m3) of a substance above 21 which it is predicted that the general population, including susceptible individuals, could 22 experience irreversible or other serious, long-lasting adverse health effects or an impaired ability 23 to escape. 24 25 AEGL-3 is the airborne concentration (expressed as ppm or mg/m3) of a substance above 26 which it is predicted that the general population, including susceptible individuals, could 27 experience life-threatening health effects or death. 28 29 Airborne concentrations below the AEGL-1 represent exposure levels that could produce 30 mild and progressively increasing but transient and nondisabling odor, taste, and sensory 31 irritation or certain asymptomatic, non-sensory effects. With increasing airborne concentrations 32 above each AEGL, there is a progressive increase in the likelihood of occurrence and the 33 severity of effects described for each corresponding AEGL. Although the AEGL values 34 represent threshold levels for the general public, including susceptible subpopulations, such as 35 infants, children, the elderly, persons with asthma, and those with other illnesses, it is recognized 36 that individuals, subject to unique or idiosyncratic responses, could experience the effects 37 described at concentrations below the corresponding AEGL. 38 39 40 2 NITROGEN MUSTARDS (HN-1, HN-2, HN-3) NAC/Interim1:11/2007 1 TABLE OF CONTENTS 2 3 4 PREFACE ...................................................................2 5 6 LIST OF TABLES.............................................................4 7 8 SUMMARY..................................................................5 9 10 1. INTRODUCTION ..........................................................9 11 12 2. HUMAN TOXICITY DATA.................................................11 13 2.1. Acute Lethality ....................................................11 14 2.2. Nonlethal Toxicity ..................................................11 15 2.2.1. Dermal Effects .............................................11 16 2.2.2. Ocular Effects ..............................................14 17 2.3. Developmental/Reproductive Effects ...................................15 18 2.4. Genotoxicity .......................................................15 19 2.5. Carcinogenicity ....................................................15 20 2.6. Summary .........................................................15 21 22 3. ANIMAL TOXICITY DATA.................................................16 23 3.1. Acute Lethality ....................................................16 24 3.2. Nonlethal Toxicity ..................................................24 25 3.3. Developmental/Reproductive Effects ...................................24 26 3.4. Genotoxicity .......................................................24 27 3.5. Carcinogenicity ....................................................24 28 3.6. Summary .........................................................24 29 30 4. SPECIAL CONSIDERATIONS...............................................24 31 4.1. Metabolism and Disposition ..........................................24 32 4.2. Mechanism of Toxicity ..............................................24 33 4.3. Structure-Activity Relationships .......................................25 34 35 5. DATA ANALYSIS FOR AEGL-1 .............................................25 36 5.1. Human Data Relevant to AEGL-1 ......................................25 37 5.2. Animal Data Relevant to AEGL-1 ......................................25 38 5.3. Derivation of AEGL-1 ...............................................25 39 40 6. DATA ANALYSIS FOR AEGL-2 .............................................25 41 6.1. Human Data Relevant to AEGL-2 ......................................25 42 6.2. Animal Data Relevant to AEGL-2 ......................................26 43 6.3. Derivation of AEGL-2 ...............................................26 44 45 3 NITROGEN MUSTARDS (HN-1, HN-2, HN-3) NAC/Interim1:11/2007 1 7. DATA ANALYSIS FOR AEGL-3 .............................................28 2 7.1. Human Data Relevant to AEGL-3 ......................................28 3 7.2. Animal Data Relevant to AEGL-3 ......................................28 4 7.3. Derivation of AEGL-3 ...............................................28 5 6 8. SUMMARY OF AEGLs.....................................................30 7 8.1. AEGL Values and Toxicity Endpoints ..................................30 8 8.2. Comparisons with Other Standards and Guidelines ........................31 9 8.3. Data Adequacy and Research Needs ....................................32 10 11 9. REFERENCES............................................................32 12 13 APPENDIX A: Derivation of AEGL Values.......................................37 14 15 APPENDIX B: Time Scaling Calculations.........................................51 16 17 APPENDIX C: Derivation Summary for Nitrogen Mustard AEGLs .....................53 18 19 APPENDIX D: Category Plots for Nitrogen Mustard AEGLs..........................63 20 21 22 LIST OF TABLES 23 24 Table 1. Chemical and physical data for HN1 ......................................9 25 Table 2. Chemical and physical data for HN2 .....................................10 26 Table 3. Chemical and physical data for HN3 .....................................10 27 Table 4. Vesicant action of nitrogen mustard vapors on forearm skin of human volunteer 28 subjects following 10-min. or 20-min. exposures ........................12 29 Table 5. Vesicant action of nitrogen mustard vapors on forearm skin of human volunteer 30 subjects following 5-min. exposures ..................................14 31 Table 6. Response of human volunteer subjects to whole-body exposure to nitrogen mustards14 32 Table 7. Estimated effects thresholds in humans exposed to nitrogen mustard vapors ......16 33 Table 8. Lethal toxicity in laboratory species following inhalation exposure to HN1 .......17 34 Table 9. Lethal toxicity in laboratory species following inhalation exposure to HN2 .......19 35 Table10. Lethal toxicity in laboratory species following inhalation exposure to HN3 .......22 36 Table 11. AEGL-1 Values For HN1, HN2, and HN3 .................................25 37 Table 12. AEGL-2 Values For HN1, HN2, and HN3 .................................28 38 Table 13. AEGL-3 Values For HN1, HN2, and HN3 .................................30 39 Table 14. Summary of AEGL Values for Nitrogen Mustards ...........................31 40 Table 15. Extant standards and guidelines for HN1, HN2, and HN3 .....................31 41 42 43 4 NITROGEN MUSTARDS (HN-1, HN-2, HN-3) NAC/Interim1:11/2007 1 SUMMARY 2 3 Nitrogen mustards are tertiary bis(β-chloroethyl)amines with vesicant activity. All are active 4 alkylating agents and ocular injurants as well. Although HN2 and HN3 were specifically 5 developed as military agents, HN1 was originally developed as a pharmaceutical. HN2 6 (mechlorethamine) later found use as a pharmaceutical. Both HN1 and HN3 are among the 7 chemical agents found in Chemical Agent Identification Sets (CAIS) that are considered a 8 component of non-stockpiled material. Development of AEGL values is limited to the nitrogen 9 mustards referred to as HN1, HN2, and HN3. 10 11 Because of the nature of the chemicals under review, military literature is a major source of the 12 relevant toxicity data.. Consequently, much of the data sources possess “limited distribution”, 13 which is a separate issue from “classification”. For various reasons, sources may possess a 14 restricted distribution because of treaty restrictions on data access with allies, concerns regarding 15 distribution of engineering information characterizing agent dissemination or generation in other 16 sections of the same document, and related issues. To ensure public access to pertinent toxicity 17 data originating from “limited distribution” materials, pertinent data from those sources have 18 been incorporated into the technical support document. 19 20 All human exposure studies
Recommended publications
  • Industry Compliance Programme
    Global Chemical Industry Compliance Programme GC-ICP Chemical Weapons Convention December 2006 Version 1.0 GLOBAL CHEMICAL INDUSTRY COMPLIANCE PROGRAMME FOR IMPLEMENTING THE CHEMICAL WEAPONS CONVENTION The purpose of the handbook is to provide guidance to chemical facilities, traders and trading companies in developing a Global Chemical Industry Compliance Programme (GC-ICP) to comply with the Chemical Weapons Convention (CWC). The GC-ICP focuses first on determining if there is a reporting requirement to your National Authority and second on collecting the relevant support data used to complete the required reports. The GC-ICP is designed to provide a methodology to comply with the CWC and establish systems that facilitate and demonstrate such compliance. Each facility/company should also ensure that it follows its country’s CWC specific laws, regulations and reporting requirements. • Sections 2, 3, and 4 guide you through the process of determining if chemicals at your facility/ company should be reported to your National Authority for compliance with the CWC. • Section 5 provides recommended guidance on information that you may use to determine your reporting requirements under the CWC and administrative tools that your facility/company may use to ensure compliance with the CWC. • Section 6 provides a glossary of terms and associated acronyms. • Section 7 provides a listing of all National Authorities by country. CWC Global Chemical Industry Compliance Programme 1 TABLE OF CONTENTS Section 1 Overview What is the Chemical Weapons Convention?
    [Show full text]
  • Page 1 EXAMPLES of ACUTE TOXINS (By CAS#) APPENDIX V(H)-B
    EXAMPLES OF ACUTE TOXINS (by CAS#) APPENDIX V(h)-B Key: SA -- Readily Absorbed Through the Skin Revised: 12/2012 ___________________________________________________ _____________ _________________________ | | | CHEMICAL NAME CAS # | SA | TARGET ORGAN | ___________________________________________________ ____________ | _ | _______________________ | AFLATOXINS 000000-00-0 | | systemic | ANILINE AND COMPOUNDS 000000-00-0 | x | blood | ARSENIC ACID AND SALTS 000000-00-0 | x | systemic | ARSENIUOS ACID AND SALTS 000000-00-0 | | systemic | ARSONIC ACID AND SALTS 000000-00-0 | | systemic | BOTULINUM TOXINS 000000-00-0 | | systemic | CYANIDE AND COMPOUNDS 000000-00-0 | x | blood | CYANOGEN AND COMPOUNDS 000000-00-0 | | blood | METHYL MERCURY AND COMPOUNDS 000000-00-0 | x | CNS | VENOM, SNAKE, CROTALUS ADAMANTEUS 000000-00-0 | | systemic | VENOM, SNAKE, CROTALUS ATROX 000000-00-0 | | systemic | MITOMYCIN C 000050-07-7 | | systemic | DINITROPHENOL, 2,4- 000051-28-5 | x | systemic | ATROPINE 000051-55-8 | x | CNS | HN2 (NITROGEN MUSTARD-2) 000051-75-2 | x | systemic | THIOTEPA 000052-24-4 | | systemic | NICOTINE 000054-11-5 | x | CNS | NITROGEN MUSTARD HYDROCHLORIDE 000055-86-7 | x | systemic | PARATHION 000056-38-2 | x | CNS | CYANIDE 000057-12-5 | x | blood | STRYCHNINE 000057-24-9 | | systemic,CNS | TUBOCURARINE CHLORIDE HYDRATE,(+)- 000057-94-3 | x | systemic | METHYL HYDRAZINE 000060-34-4 | x | pulmonary,CNS,blood | ANILINE 000062-53-3 | x | blood | DICHLORVOS 000062-73-7 | x | systemic | SODIUM FLUOROACETATE 000062-74-8 | x | systemic | COLCHICINE
    [Show full text]
  • A Quantum Chemical Study Involving Nitrogen Mustards
    The Pharmaceutical and Chemical Journal, 2016, 3(4):58-60 Available online www.tpcj.org ISSN: 2349-7092 Research Article CODEN(USA): PCJHBA Formation enthalpy and number of conformers as suitable QSAR descriptors: a quantum chemical study involving nitrogen mustards Robson Fernandes de Farias Universidade Federal do Rio Grande do Norte, Cx. Postal 1664, 59078-970, Natal-RN, Brasil Abstract In the present work, a quantum chemical study (Semi-empirical,PM6 method) is performed using nitrogen mustards (HN1, HN2 and HN3) as subjects in order to demonstrate that there is a close relationship between pharmacological activity and parameters such as formation enthalpy and number of conformers, which could, consequently, be employed as reliable QSAR descriptors. To the studied nitrogen mustards, a very simple equation o o relating log P, ΔH f and the number of conformers (Nc) was found: log P = [(log -ΔH f + logNc)/2]-0.28. Keywords QSAR, Descriptors, Formation enthalpy, Conformers, Semi-empirical, Nitrogen mustards, Log P Introduction It is well known that lipophilicity is a very important molecular descriptor that often correlates well with the bioactivity of chemicals [1]. Hence, lipophilicity, measured as log P, is a key property in quantitative structure activity relationship (QSAR) studies. In this connection, in the pharmaceutical sciences it is a common practice to use log P (the partition coefficient between water and octanol), as a reliable indicator of the hydrophobicity or lipophilicity of (drug) molecules [1-2]. For example, relying primarily on the log P is a sensible strategy in preparing future 18-crown-6 analogs with optimized biological activity [3].
    [Show full text]
  • The Chemotherapy of Malignant Disease -Practical and Experimental Considerations
    Postgrad Med J: first published as 10.1136/pgmj.41.475.268 on 1 May 1965. Downloaded from POSTGRAD. MED. J. (1965), 41,268 THE CHEMOTHERAPY OF MALIGNANT DISEASE -PRACTICAL AND EXPERIMENTAL CONSIDERATIONS JOHN MATTHIAS, M.D., M.R.C.P., F.F.A., R.C.S. Physician, The Royal Marsden Hospital, London, S.W.3. THE TERM chemotherapy was introduced by positively charged alkyl (CH2) radicles of Ehrlich to describe the specific and effective the agent. treatment of infectious disease by chemical (a) The nitrogen mustards: mustine (HN2 substances. It is currently also applied to the 'nitrogen mustard', mechlorethamine, treatment of malignant disease. Unfortunately mustargen), trimustine (Trillekamin no aspect of tumour metabolism has been HN3), chlorambucil (Leukeran, phenyl discovered which has allowed the development butyric mustard), melphalan (Alkeran, of drugs capable of acting specifically upon the phenyl alanine mustard), uramustine malignant cell, so that cytotoxic drugs also (Uracil mustard), cyclophosphamide affect normal cells to a greater or lesser degree. (Endoxan or Cytoxan), mannomustine The most susceptible or sensitive of the normal (DegranoO). tissues are those with the highest rates of cell (b) The ethylenamines: tretamine (trie- turnover and include the haemopoietic and thanomelamine, triethylene melamine, lympho-reticular tissues, the gastro-intestinal TEM), thiotepa (triethylene thiopho- the the testis and the hair epithelium, ovary, sphoramide), triaziquone (Trenimon).by copyright. follicles. (c) The epoxides: triethyleneglycoldigly- Cancer chemotherapy may be said to encom- cidyl ether (Epodyl). pass all treatments of a chemical nature (d) The sulphonic acid esters: busulphan administered to patients with the purpose of (Myleran), mannitol myleran. restricting tumour growth or destroying tumour 2.
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • Chapter III. a Review of Spiking Chemicals Used in the First 40 OPCW Proficiency Tests
    RECOMMENDED OPERATION PROCEDURES FOR CWC-RELATED ANALYSIS Section 5. Reporting Chapter III. A review of spiking chemicals used in the first 40 OPCW Proficiency Tests Chapter III. A review of spiking chemicals used in the first 40 OPCW Proficiency Tests Authors Keith Norman, Stephen Johnson Cranfield Forensic Institute Cranfield University Defence Academy of the United Kingdom Shrivenham, Swindon SN6 8LA, UK E-mail: [email protected], [email protected] Reviewers Hugh Gregg Organisation for the Prohibition of Chemical Weapons Johan de Wittlaan 32, 2517 JR, The Hague, The Netherlands E-mail: [email protected] Harri Kiljunen Finnish Institute for Verification of the Chemical Weapons Convention (VERIFIN) P.O. Box 55, FI-00014 University of Helsinki, Finland E-mail: [email protected] Chua Hoe Chee DSO National Laboratories, 12 Science Park Drive, Singapore 118225 E-mail: [email protected] Peter Siegenthaler Spiez Laboratory, Austrasse,CH-3700 Spiez, Switzerland E-mail: [email protected] 1. Scope From 1997 until 2016, the Organisation for the Prohibition of Chemical Weapons (OPCW) has coordinated 40 proficiency tests for the analysis and identification of intact chemical warfare agents, precursor chemicals, degradation and reaction products. This chapter reviews the chemicals used to spike the proficiency test samples, identifying those that have been used multiple times and the distribution of chemicals based upon the schedules in the chemical warfare convention (CWC). The aim of this chapter is not to provide an easy route to pass the proficiency tests but rather to illustrate the range of chemicals that should be considered during method development and/or validation for laboratories participating in, or considering participating in the OPCW Proficiency Test regime.
    [Show full text]
  • Nerve Agent - Lntellipedia Page 1 Of9 Doc ID : 6637155 (U) Nerve Agent
    This document is made available through the declassification efforts and research of John Greenewald, Jr., creator of: The Black Vault The Black Vault is the largest online Freedom of Information Act (FOIA) document clearinghouse in the world. The research efforts here are responsible for the declassification of MILLIONS of pages released by the U.S. Government & Military. Discover the Truth at: http://www.theblackvault.com Nerve Agent - lntellipedia Page 1 of9 Doc ID : 6637155 (U) Nerve Agent UNCLASSIFIED From lntellipedia Nerve Agents (also known as nerve gases, though these chemicals are liquid at room temperature) are a class of phosphorus-containing organic chemicals (organophosphates) that disrupt the mechanism by which nerves transfer messages to organs. The disruption is caused by blocking acetylcholinesterase, an enzyme that normally relaxes the activity of acetylcholine, a neurotransmitter. ...--------- --- -·---- - --- -·-- --- --- Contents • 1 Overview • 2 Biological Effects • 2.1 Mechanism of Action • 2.2 Antidotes • 3 Classes • 3.1 G-Series • 3.2 V-Series • 3.3 Novichok Agents • 3.4 Insecticides • 4 History • 4.1 The Discovery ofNerve Agents • 4.2 The Nazi Mass Production ofTabun • 4.3 Nerve Agents in Nazi Germany • 4.4 The Secret Gets Out • 4.5 Since World War II • 4.6 Ocean Disposal of Chemical Weapons • 5 Popular Culture • 6 References and External Links --------------- ----·-- - Overview As chemical weapons, they are classified as weapons of mass destruction by the United Nations according to UN Resolution 687, and their production and stockpiling was outlawed by the Chemical Weapons Convention of 1993; the Chemical Weapons Convention officially took effect on April 291997. Poisoning by a nerve agent leads to contraction of pupils, profuse salivation, convulsions, involuntary urination and defecation, and eventual death by asphyxiation as control is lost over respiratory muscles.
    [Show full text]
  • Salvage Chemotherapy for Recurrent Primary Brain Tumors in Children
    Salvage chemotherapy for recurrent primary brain tumors in children Jan van Eys, PhD, MD, Tallie Z. Baram, MD, PhD, Ayten Cangir, MD, Janet M. Bruner, MD, and J. Martinez-Prieto, MD From the Departments of Pediatrics, Neurooncology, and Pathology, The Universityof Texas M, D. Anderson Cancer Center at Houston Sixty consecutive evaluable children with recurrent primary tumors of the central nervous system were treated with a regimen of vincristine, nitrogen mustard, procarbazine, and prednisone over a 12-year period. Tumor types included medulloblastoma (19), brain-stem glioma (16), astrocytoma (13), and a miscellaneous glioma (12). Responses and sustained survivals were achieved. Responses were highly dependent on tumor type. Disease progres- sion was halted in 73% of the children with medulloblastoma, and three have survived in complete remission for more than 10 years from the start of therapy with vincristine, nitrogen mustard, procarbazine, and prednisone. Two of four patients with anaplastic glioma, are long-term survivors. In contrast, less than one third of children with brain-stem gliomas responded. Toxicity consisted mainly of neutropenia, thrombocytopenia, infections, and rarely a procarba- zine rash. (J PEDIAI'R1988;113:601-6) Therapy for recurrent brain tumors in children remains METHODS unsatisfactory; most die of their disease regardless of Patients. Sixty-five children with a median age of 6 therapy, l We have repbrted on the responsiveness of years (range, 1 to 16 years) were treated with MOPP for recurrent brain tumors in children to chemotherapy with recurrent brain tumors. Sixty patients were eligible for vincristine, nitrogen mustard, procarbazine, and predni- evaluation; the other five patients were excluded because 1 sone.
    [Show full text]
  • Anticancer Alkylating Agents-Part-I.Pdf
    Anticancer Agents Medicinal Chemistry III B Pharm Dr. bilal al-jaidi Assistant Professor, Pharmaceutical Medicinal Chemistry Faculty of Pharmacy, Philadelphia University-Jordan Email: [email protected] Learning Outcome At the end of this lesson students will be able to – Outline the current status, causes and treatment strategies of cancer – Explain the mechanism of action, SAR, therapeutic uses and side effects of following classes of anti-cancer agents: • Alkylating Agents QUIZ = 20 Marks • Heavy metal compounds (Metallating Agents) • Anti-metabolite • Antibiotics • Plant Extracts • Topoisomerase inhibitors • Hormones • Combination of chemotherapy with other treatments • Others First Examination= 20 Marks The Status of Cancer • Cancer is a leading cause of death worldwide, accounting for 12.6 million new cases and 7.6 million deaths every year. THIS IS EQUIVALENT TO ONE PERSON, EVERY 5 SECONDS OF EVERYDAY Source: GLOBOCAN 2008 By 2020 the World Health Organisation (WHO) expects this rise to 16 million. Cancer • A new growth of tissue in which multiplication of cells is uncontrolled and progressive (tumour). • Abnormal cells can spread to other parts of the body (metastasise). Cancer Types Cancer types are categorized based on the functions/locations of the cells from which they originate: Carcinoma: a tumor derived from epithelial cells, those cells that line the inner or outer surfaces of our skin and organs (80-90% of all cancer cases reported) Sarcoma: a tumor derived from muscle, bone, cartilage, fat or connective tissues. Leukemia: a cancer derived from white blood cells or their precursors. Lymphoma: a cancer of bone marrow derived cells that affects the lymphatic system. Myelomas: a cancer involving the white blood cells responsible for the production of antibodies (B lymphocytes).
    [Show full text]
  • The Nitrogen Mustard Anticancer Agent Mechlorethamine Generates Cross-Links Deri
    Article pubs.acs.org/biochemistry A New Cross-Link for an Old Cross-Linking Drug: The Nitrogen Mustard Anticancer Agent Mechlorethamine Generates Cross-Links Derived from Abasic Sites in Addition to the Expected Drug-Bridged Cross-Links Maryam Imani Nejad,† Kevin M. Johnson,† Nathan E. Price,† and Kent S. Gates*,†,‡ † Department of Chemistry, University of Missouri, 125 Chemistry Building, Columbia, Missouri 65211, United States ‡ Department of Biochemistry, University of Missouri, 125 Chemistry Building, Columbia, Missouri 65211, United States *S Supporting Information ABSTRACT: Nitrogen mustard anticancer drugs generate highly reactive aziridinium ions that alkylate DNA. Mono- adducts arising from reaction with position N7 of guanine residues are the major DNA adducts generated by these agents. Interstrand cross-links in which the drug bridges position N7 of two guanine residues are formed in low yields relative to those of the monoadducts but are generally thought to be central to medicinal activity. The N7-alkylguanine residues generated by nitrogen mustards are depurinated to yield abasic (Ap) sites in duplex DNA. Here, we show that Ap sites generated by the nitrogen mustard mechlorethamine lead to interstrand cross-links of a type not previously associated with this drug. Gel electrophoretic data were consistent with early evolution of the expected drug-bridged cross-links, followed by the appearance of Ap-derived cross-links. The evidence is further consistent with a reaction pathway involving alkylation of a guanine residue in a 5′-GT sequence, followed by depurination to generate the Ap site, and cross-link formation via reaction of the Ap aldehyde residue with the opposing adenine residue at this site [Price, N.
    [Show full text]
  • Covalent Protein Adduction of Nitrogen Mustards and Related Compounds Vanessa R
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 2-28-2014 Covalent Protein Adduction of Nitrogen Mustards and Related Compounds Vanessa R. Thompson Florida International University, [email protected] DOI: 10.25148/etd.FI14040835 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Amino Acids, Peptides, and Proteins Commons, and the Analytical Chemistry Commons Recommended Citation Thompson, Vanessa R., "Covalent Protein Adduction of Nitrogen Mustards and Related Compounds" (2014). FIU Electronic Theses and Dissertations. 1152. https://digitalcommons.fiu.edu/etd/1152 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida COVALENT PROTEIN ADDUCTION OF NITROGEN MUSTARDS AND RELATED COMPOUNDS A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Vanessa Thompson 2014 To: Dean Kenneth G. Furton College of Arts and Sciences This dissertation, written by Vanessa Thompson, and entitled Covalent Protein Adduction of Nitrogen Mustards and Related Compounds, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Fenfei Leng _______________________________________ Watson Lees _______________________________________ Dietrich Lorke _______________________________________ Bruce McCord _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: February 27, 2014 The dissertation of Vanessa Thompson is approved.
    [Show full text]
  • SUMMARY of PARTICULARLY HAZARDOUS SUBSTANCES (By
    SUMMARY OF PARTICULARLY HAZARDOUS SUBSTANCES (by alpha) Key: SC -- Select Carcinogens RT -- Reproductive Toxins AT -- Acute Toxins SA -- Readily Absorbed Through the Skin DHS -- Chemicals of Interest Revised: 11/2012 ________________________________________________________ ___________ _ _ _ _ _ _ _ _ _ _ _ ||| | | | CHEMICAL NAME CAS # |SC|RT| AT | SA |DHS| ________________________________________________________ ___________ | _ | _ | _ | _ | __ | | | | | | | 2,4,5-T 000093-76-5 | | x | | x | | ABRIN 001393-62-0 | | | x | | | ACETALDEHYDE 000075-07-0 | x | | | | | ACETAMIDE 000060-35-5 | x | | | | | ACETOHYDROXAMIC ACID 000546-88-3 ||x| | x | | ACETONE CYANOHYDRIN, STABILIZED 000075-86-5 | | | x | | x | ACETYLAMINOFLUORENE,2- 000053-96-3 | x | | | | | ACID MIST, STRONG INORGANIC 000000-00-0 | x | | | | | ACROLEIN 000107-02-8 | | x | x | x | | ACRYLAMIDE 000079-06-1 | x | x | | x | | ACRYLONITRILE 000107-13-1 | x | x | x | x | | ACTINOMYCIN D 000050-76-0 ||x| | x | | ADIPONITRILE 000111-69-3 | | | x | | | ADRIAMYCIN 023214-92-8 | x | | | | | AFLATOXIN B1 001162-65-8 | x | | | | | AFLATOXIN M1 006795-23-9 | x | | | | | AFLATOXINS 001402-68-2 | x | | x | | | ALL-TRANS RETINOIC ACID 000302-79-4 | | x | | x | | ALPRAZOMAN 028981-97-7 | | x | | x | | ALUMINUM PHOSPHIDE 020859-73-8 | | | x | | x | AMANTADINE HYDROCHLORIDE 000665-66-7 | | x | | x | | AMINO-2,4-DIBROMOANTHRAQUINONE 000081-49-2 | x | | | | | AMINO-2-METHYLANTHRAQUINONE, 1- 000082-28-0 | x | | | | | AMINO-3,4-DIMETHYL-3h-IMIDAZO(4,5f)QUINOLINE,2- 077094-11-2 | x | | | | | AMINO-3,8-DIMETHYL-3H-IMIDAZO(4,5-f)QUINOXALINE,
    [Show full text]